Curis 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth

Curis reported its fiscal 2025 Q2 earnings on August 6, 2025, delivering revenue growth that exceeded prior performance, though the company remains unprofitable. The results reflected improved financial discipline, with both per-share and net losses significantly reduced year-over-year. While no formal guidance adjustments were provided, the company outlined continued clinical trial enrollment and regulatory strategy for key drug candidates.

Revenue
Curis reported total revenue of $2.75 million in Q2 2025, representing an 8.0% increase compared to $2.55 million in the same period of 2024.

Earnings/Net Income
The company narrowed its per-share loss to $0.68 in 2025 Q2 from $2.03 in 2024 Q2, marking a 66.5% improvement. Net losses also decreased to $-8.59 million, down 27.2% from $-11.80 million in the prior-year period. Despite the reduction, the company continues to operate at a loss, though the trend indicates a positive trajectory in cost management.

Price Action
CRIS shares have faced downward pressure, falling 2.34% in the most recent trading day, 5.11% for the week, and 7.73% month-to-date.

Post-Earnings Price Action Review
A post-earnings strategy of buying CRIS following a revenue beat and holding for 30 days yielded a poor return of -89.83%, underperforming the benchmark by 174.25%. The strategy exhibited a maximum drawdown of 0% and a Sharpe ratio of -0.29, highlighting its high risk and unprofitability.

CEO Commentary
James Dentzer, CEO of Curis, highlighted progress in the TakeAim Lymphoma study, with enrollment ongoing in both BTKi-experienced and BTKi-naïve PCNSL patients. The CEO expressed optimism about a new clinical study of emavusertib in combination with a BTK inhibitor in Chronic Lymphocytic Leukemia, aiming to enhance treatment outcomes and achieve complete remission or MRD negativity. He emphasized the potential of this combination to represent a paradigm shift in CLL management and noted plans to begin enrollment later in 2025.

Guidance
Curis provided a forward-looking financial outlook, focusing on continued enrollment in key clinical trials and regulatory filings for emavusertib in PCNSL, AML, and MDS. The company expects to fund operations through Q1 2026 and anticipates additional data from the TakeAim Lymphoma study later in the year to support future regulatory submissions. No specific revenue or EPS targets were provided.

Additional News
The latest quarterly report from Reportify, dated August 6, 2025, reiterates the filing of Curis’ Q2 2025 results, though the provided content primarily replicates the existing earnings disclosure without introducing new financial or strategic updates. No M&A activity, executive changes, or dividend announcements were reported in the additional news section.